Healthy
Conditions
Brief summary
* Objective: * To compare the rate and extent of absorption of Zolpidem Tablets 10mg: Test Product: Zolpidem Tablets 10mg manufactured by Torrent Pharmaceuticals Limited, India Reference Product: Ambien® Tablets 10 mg (Reference Listed Drug) manufactured by Sanofi- Synthelabo Inc. under fasting conditions in 24 healthy, adult, human subjects. * Study Design: * Open label, randomized, two-period, two-treatment, two-sequence single dose crossover design.
Detailed description
Open label, randomized, two-period, two-treatment, two-sequence single dose
Interventions
Sponsors
Torrent Pharmaceuticals Limited
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Inclusion criteria
1. Male and female subjects in the range of 18 - 45 years of age. 2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart. (Appendix A) 3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and body temperature) 4. Subjects with normal findings as determined by hematological tests, serum chemistry, urine analysis, ECG and X-ray. 5. Willingness to follow the protocol requirement as evidenced by written, informed consent. 6. Agreeing to, not using any medication (prescription and over the counter), including vitamins and minerals for 15 days prior to study and during the course of the study. 7. No history or presence of significant alcoholism or drug abuse in the past one year. 8. Non-smokers, ex smokers and light smokers will be included. Light smokers are defined as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely stopped smoking for at least 3 months.
Exclusion criteria
1. Requiring medication for any ailment including enzyme-modifying drugs Use of any drugs known to induce or inhibit hepatic drug metabolism (e.g.s, inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors: SSRIs, cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication. 2. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc. 3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic diseases. 4. History of psychiatric disorder or history of suicide attempt. 5. Participation in a clinical drug study or bioequivalence study 90 days prior to present study. 6. History of malignancy or other serious diseases. 7. Refusal to abstain from food for ten (10) hours prior to study drug administration the day of each study period and for four (4) additional hours each, post dose. 8. Refusal to abstain from water for one (1) hour prior to study drug administration the day of each study period and for two (2) additional hour, post dosing. 9. Any contraindication to blood sampling. 10. Refusal to abstain from smoking or consumption of tobacco products 24 hours before dosing until last sample collection of each period. Habituation of tobacco necessitating uninterrupted tobacco consumption. 11. Use of xanthine-containing beverages or food for 48 hours prior to each drug dose. 12. Blood donation 90 days prior to the commencement of the study. 13. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests. 14. Known history of allergic reactions to zolpidem or other related drugs. 15. History of drug abuse in the past one year. 16. Use of prescription medication within 14 days prior to administration of study medication or over the counter products (including natural food supplements, vitamins, garlic as a supplement) within 2 weeks prior to administration of study medication, except for topical products without systemic absorption. 17. Pregnant and lactating women. * At the time of screening, prior to enrollment, presence of pregnancy will be confirmed by urine pregnancy test. * Female subjects not confirming to using birth control measures, from the date of screening till the completion of the second period of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable. Use of hormonal contraceptives either oral or implants will not be acceptable. 18. Female subjects whose menstruation cycle coincides with the study periods.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. | The maximum or peak concentration that the drug reaches in the plasma |
| Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] | plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. | The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t) |
| The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞) | plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. | The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. |
Countries
India
Participant flow
Pre-assignment details
healthy, normal subjects
Participants by arm
| Arm | Count |
|---|---|
| Experimental Torrent's Zolpidem Tartrate Tablets 10 mg | 12 |
| Active Comparator Ambien® 10mg tablets | 12 |
| Total | 24 |
Baseline characteristics
| Characteristic | Active Comparator | Experimental | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 12 Participants | 24 Participants |
| Age Continuous | 28.2 years STANDARD_DEVIATION 6.7 | 28.2 years STANDARD_DEVIATION 6.7 | 28.2 years STANDARD_DEVIATION 6.7 |
| Region of Enrollment India | 12 participants | 12 participants | 24 participants |
| Sex: Female, Male Female | 4 Participants | 4 Participants | 8 Participants |
| Sex: Female, Male Male | 8 Participants | 8 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 9 / 24 | 0 / 24 |
| serious Total, serious adverse events | 0 / 24 | 0 / 24 |
Outcome results
Primary
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)
Time frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental | Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] | 751.31 mcg*hr/mL | Standard Deviation 399.17 |
| Active Comparator | Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] | 717.71 mcg*hr/mL | Standard Deviation 401.92 |
Primary
Maximum Plasma Concentration (Cmax)
The maximum or peak concentration that the drug reaches in the plasma
Time frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental | Maximum Plasma Concentration (Cmax) | 177.69 ng/ml | Standard Deviation 57.05 |
| Active Comparator | Maximum Plasma Concentration (Cmax) | 172.64 ng/ml | Standard Deviation 72.15 |
Primary
The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.
Time frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental | The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞) | 778.16 mcg*hr/mL | Standard Deviation 418.74 |
| Active Comparator | The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞) | 741.65 mcg*hr/mL | Standard Deviation 415.73 |